DPP4 and atrial fibrillation: Another trial based on a Taiwanese multi-center healthcare provider reports a lower incidence rate of atrial fibrillation after SGLT2 inhibitor treatment compared to dipeptidyl peptidase 4 (DPP4) inhibitor treatment in more than 25,000 patients.